US Patent Issued to LENTIGEN TECHNOLOGY, The United States of America, as represented by the Secretary, Department of Health and Human Services on Feb. 3 for "Compositions and methods for treating cancer with anti-ROR1 immunotherapy" (Maryland, Washington Inventors)

ALEXANDRIA, Va., Feb. 3 -- United States Patent no. 12,540,179, issued on Feb. 3, was assigned to LENTIGEN TECHNOLOGY INC. (Gaithersburg, Md.) and The United States of America, as represented by the Secretary, Department of Health and Human Services (Bethesda, Md.).

"Compositions and methods for treating cancer with anti-ROR1 immunotherapy" was invented by Rimas J. Orentas (Seattle), Dina Schneider (Potomac, Md.), Boro Dropulic (Ellicott City, Md.), Dimiter S. Dimitrov (Frederick, Md.) and Zhongyu Zhu (Frederick, Md.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Chimeric antigen receptors containing ROR1 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antige...